Olmesartan medoxomil, classified as BCS class II due to its poor water solubility, exhibits a low oral bioavailability of 28.6%. Microballoons of Olmesartan medoxomil were formulated using the ionotro
Cardiovascular disease is a significant and ever-growing concern, causing high morbidity and mortality worldwide. Conventional therapy is often very precarious and requires long-term usage. Several ph
Lipid nanoparticles (LNPs) and vesicles are emerging classes of novel therapeutics. However, LNP formulations possess many different internal structures, and particle structure heterogeneity within sa
